[1. W. H. C. Burgdorf, G. Plewig, H. H. Wolff, M. Landthale and O. Braun-Falco, Braun-Falco’s Dermatology, Springer Verlag, Berlin-Heidelberg 2009.10.1007/978-3-540-29316-3]Search in Google Scholar
[2. B. Bergler-Czop, Nowy Schemat Terapii Różnych Postaci Trądziku Oparty na Analizie Skórno-Śluzówkowych Objawów Ubocznych Stosowania Retinoidów oraz Stężeń Cytokin Prozapalnych - A New Therapy Scheme of Various Kinds of Acne Based on Skin-mucosal Side-effects of Retinoid Treatment and Pro-inflammatory Cytokines Levels, Ph. D. Thesis, Medical University of Silesia, Publisher Tekst, Katowice 2011.10.3109/15569527.2011.63394922103810]Search in Google Scholar
[3. E. Papakonstantinou, A. J. Aletras, E. Glass, P. Tsogas, A. Dionyssopoulos, J. Adjaye, S. Fimmel, P. Gouvousis, R. Herwig, H. Lehrach, C. C. Zouboulis and G. Karakiulakis, Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin, J. Invest. Dermatol. 125 (2005) 673-684.10.1111/j.0022-202X.2005.23848.x16185265]Search in Google Scholar
[4. B. Bergler-Czop and L. Brzezińska-Wcisło, Pro-inflammatory cytokines in patients with various kinds of acne treated with isotretinoin, Postepy Dermatol. Alergol. 31 (2014) 21-28; DOI: 10.5114/ pdia.2014.40655.10.5114/pdia.2014.40655395205124683393]Search in Google Scholar
[5. L. Beckenbach, J. M. Baron, H. F. Merk, H. Löffler and P. M. Amann, Retinoid treatment of skin diseases, Eur. J. Dermatol. 25 (2015) 384-391; DOI: 10.1684/ejd.2015.2544.10.1684/ejd.2015.254426069148]Search in Google Scholar
[6. S. C. On and J. Zeichner, Isotretinoin updates, Dermatol. Ther. 26 (2013) 377-389; DOI: 10.1111/dth.12084.10.1111/dth.1208424099068]Search in Google Scholar
[7. G. Carretero, M. Ribera, I. Belinchón, J. M. Carrascosa, L. Puig, C. Ferrandiz, L. Dehesa, D. Vidal, F. Peral, E. Jorquera, A. González-Quesada, C. Muñoz, J. Notario, F. Vanaclocha and J. C. Moreno, Psoriasis group of the AEDV. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology, Actas Dermosifiliogr. 104 (2013) 598-616; DOI: 10.1016/j.adengl.2013.01.001.10.1016/j.adengl.2013.01.00123891453]Search in Google Scholar
[8. U. Cegieła, J. Folwarczna, R. Janiec and W. Janiec, Kompendium Farmakologii, Państwowy Zakład Wydawnictw Lekarskich Publishing, Warsaw 2012, pp. 400-402.]Search in Google Scholar
[9. K. H. Dragnev, W. J. Petty, S. J. Shah, L. D. Lewis, C. C. Black, V. Memoli, W. C. Nugent, T. Hermann, A. Negro-Vilar, J. R. Rigas and E. Dmitrovsky, A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer, Clin. Cancer Res. 13 (2007) 1794-1800.10.1158/1078-0432.CCR-06-183617363535]Search in Google Scholar
[10. A. L. Zaenglein, A. L. Pathy, B. J. Schlosser, A. Alikhan, H. E. Baldwin, D. S. Berson, W. P. Bowe, E. M. Graber, J. C. Harper, S. Kang, J. E. Keri, J. J. Leyden, R. V. Reynolds, N. B. Silverberg, L. F. Stein Gold, M. M. Tollefson, J. S. Weiss, N. C. Dolan, A. A. Sagan, M. Stern, K. M. Boyer and R. Bhushan, Guidelines of care for the management of acne vulgaris, J. Am. Acad. Dermatol. (2016) in press; DOI: 10.1016/j.jaad.2015.12.037.10.1016/j.jaad.2015.12.03726897386]Search in Google Scholar
[11. H. E. Baldwin, M. Nighland, B. Kendall, D. A. Mays, R. Grossman and J. Newburger, 40 years of topical tretinoin use in review, J. Drugs Dermatol. 12 (2013) 638-642.]Search in Google Scholar
[12. G. Shiva, M. Somaye and J. M. Reza, Improved photostability, reduced skin permeation and irritation of isotretinoin by solid lipid nanoparticles, Acta Pharm. 62 (2012) 547-562; DOI: 10.2478/v10007-012-0032-z.10.2478/v10007-012-0032-z23333889]Search in Google Scholar
[13. F. T. Fraunfelder, F. W. Fraunfelder and R. Edwards, Ocular side effects possibly associated with isotretinoin usage, Am. J. Ophthalmol. 132 (2001) 299-305; DOI: 10.1016/S0002-9394(01)01024-8.10.1016/S0002-9394(01)01024-8]Search in Google Scholar
[14. A. Karalezli, M. Borazan, D. D.Altinors, R. Dursun, H. Kiyici and Y. A. Akova, Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin, Cornea 28 (2009) 46-50; DOI: 10.1097/ICO.0b013e318183a396.10.1097/ICO.0b013e318183a39619092405]Search in Google Scholar
[15. M. J. Ju, J. G. Shin, S. Hoshi, Y. Yasuno, B. H. Lee, S. Tang and T. J. Eom, Three-dimensional volumetric human meibomian gland investigation using polarization-sensitive optical coherence tomography, J. Biomed. Opt. 19 (2014) ID 030503; DOI: 10.1117/1.JBO.19.3.030503.10.1117/1.JBO.19.3.03050324604532]Search in Google Scholar
[16. R. W. Lambert and R. E. Smith, Pathogenesis of blepharoconjunctivitis complicating 13-cis-retinoic acid (isotretinoin) therapy in a laboratory model, Invest. Ophthalmol. Vis. Sci. 29 (1988) 1559-1564.]Search in Google Scholar
[17. W. D. Mathers, W. J. Shields, M. S. Sachde, W. M. Petroll and J. V. Jester, Meibomian gland morphology and tear osmolarity: changes with Accutane therapy, Cornea 10 (1991) 286-290.]Search in Google Scholar
[18. M. Neudorfer, I. Goldshtein, O. Shamai-Lubovitz, G. Chodick, Y. Dadon and V. Shalev, Ocular adverse effects of systemic treatment with isotretinoin, Arch. Dermatol. 148 (2012) 803-808; DOI: 10.1001/archdermatol.2012.352.10.1001/archdermatol.2012.35222508771]Search in Google Scholar
[19. T. Cumurcu, E. Sezer, R. Kilic and Y. Bulut, Comparison of dose-related ocular side effects during systemic isotretinoin administration, Eur. J. Ophthalmol. 19 (2009) 196-200.10.1177/11206721090190020419253234]Search in Google Scholar
[20. M. Brelsford and T. C. Beute, Preventing and managing the side effects of isotretinoin, Semin. Cutan. Med. Surg. 27 (2008) 197-206; DOI: 10.1016/j.sder.2008.07.002.10.1016/j.sder.2008.07.00218786498]Search in Google Scholar
[21. P. A. Sieving, P. Chaudhry, M. Kondo, M. Provenzano, D. Wu, T. J. Carlson, R. A. Bush and D. A. Thompson, Inhibition of the visual cycle in vivo by 13-cis-retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy, Proc. Natl. Acad. Sci. USA 98 (2001) 1835-1840; DOI: 10.1073/pnas.98.4.1835.10.1073/pnas.98.4.18352934311172037]Search in Google Scholar
[22. S. P. Mollan, M. Woodcock, R. Siddiqi, J. Huntbach, P. Good and R. A. H. Scott, Does use of isotretinoin rule out a career in flying? Br. J. Ophthalmol. 90 (2006) 957-959; DOI: 10.1136/bjo.2006.092833.10.1136/bjo.2006.092833185720916723361]Search in Google Scholar
[23. J. Santodomingo-Rubido, E. Barrado-Navascués and M. J. Rubido-Crespo, Drug-induced ocular sideeffects with isotretinoin, Ophthalmic Physiol. Opt. 28 (2008) 497-501; DOI: 10.1111/j/1475-1313.2008.00590.x.]Search in Google Scholar
[24. H. I. Onder, H. Turan, A. C. Kilic, M. Kaya and M. Tunc, Premacular hemorrhage due to isotretinoin use, Cutan. Ocul. Toxicol. 32 (2013) 170-172; DOI: 10.3109/15569527.2012.676121.10.3109/15569527.2012.67612122510043]Search in Google Scholar
[25. H. Gursoy, I. Cakmak, N. Yildirim and H. Basmak, Presumed isotretinoin-induced, concomitant autoimmune thyroid disease and ocular myasthenia gravis: a case report, Case Rep. Dermatol. 4 (2012) 256-260; DOI: 10.1159/000345680. 10.1159/000345680353195723275770]Search in Google Scholar